Literature DB >> 12036828

Skeletal aspects of Gaucher disease: a review.

R J Wenstrup1, M Roca-Espiau, N J Weinreb, B Bembi.   

Abstract

In Gaucher disease, a genetic deficiency in the activity of the lysosomal enzyme beta-glucocerebrosidase (acid beta-glucosidase) causes monocytes and macrophages to store excessive amounts of glucocerebroside in lysosomes. The resulting distended cells are called Gaucher cells, and the pathology associated with this condition stems from the accumulation of Gaucher cells in organ systems. The skeletal manifestations are probably the most disabling aspect of the disease. Patients commonly experience bone pain, some suffer bone crises, and up to 20% have impaired mobility. Radiological findings include Erlenmeyer flask deformity, osteopenia, osteosclerosis, osteonecrosis, fractures and bone marrow infiltration. Findings from the Gaucher Registry show that nearly all patients with Gaucher disease have radiological evidence of skeletal involvement, and the majority have a history of serious skeletal complications. Skeletal involvement follows three basic processes: focal disease (irreversible lesions such as osteonecrosis and osteosclerosis), local disease (reversible abnormalities adjacent to heavily involved marrow such as cortical thinning and long bone deformity) and generalized osteopenia. Infarctions are involved in some of the skeletal manifestations, but the mechanisms causing high rates of bone turnover and failure of remodelling are not known. The availability of a beta-glucocerebrosidase-deficient mouse model of Gaucher disease with long-term survival should help elucidate the skeletal pathology in Gaucher disease and may ultimately lead to improved management of skeletal complications.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036828     DOI: 10.1259/bjr.75.suppl_1.750002

Source DB:  PubMed          Journal:  Br J Radiol        ISSN: 0007-1285            Impact factor:   3.039


  50 in total

1.  Skeletal manifestations in pediatric and adult patients with Niemann Pick disease type B.

Authors:  Melissa Wasserstein; James Godbold; Margaret M McGovern
Journal:  J Inherit Metab Dis       Date:  2012-06-21       Impact factor: 4.982

Review 2.  Radiological aspects of Gaucher disease.

Authors:  Robert Katz; Tom Booth; Rikin Hargunani; Peter Wylie; Brian Holloway
Journal:  Skeletal Radiol       Date:  2010-07-25       Impact factor: 2.199

3.  Quantifying the Erlenmeyer flask deformity.

Authors:  A Carter; P S Rajan; P Deegan; T M Cox; P Bearcroft
Journal:  Br J Radiol       Date:  2011-10-18       Impact factor: 3.039

4.  Jaw bones' involvement and dental features of type I and type III Gaucher disease: a radiographic study of 42 paediatric patients.

Authors:  Y S A Mohamed; M K Zayet; O M Omar; A M El-Beshlawy
Journal:  Eur Arch Paediatr Dent       Date:  2019-09-17

Review 5.  Gaucher disease: the metabolic defect, pathophysiology, phenotypes and natural history.

Authors:  Hagit N Baris; Ian J Cohen; Pramod K Mistry
Journal:  Pediatr Endocrinol Rev       Date:  2014-09

6.  Correlation of MRI-Based bone marrow burden score with genotype and spleen status in Gaucher's disease.

Authors:  Robert F DeMayo; Andrew H Haims; Matthew C McRae; Ruhua Yang; Pramod K Mistry
Journal:  AJR Am J Roentgenol       Date:  2008-07       Impact factor: 3.959

7.  Real-world clinical experience with long-term miglustat maintenance therapy in type 1 Gaucher disease: the ZAGAL project.

Authors:  Pilar Giraldo; Pilar Alfonso; Koldo Atutxa; María A Fernández-Galán; Abelardo Barez; Rafael Franco; Dora Alonso; Alejandro Martin; Paz Latre; Miguel Pocovi
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

Review 8.  The Erlenmeyer flask bone deformity in the skeletal dysplasias.

Authors:  Maha A Faden; Deborah Krakow; Fatih Ezgu; David L Rimoin; Ralph S Lachman
Journal:  Am J Med Genet A       Date:  2009-06       Impact factor: 2.802

Review 9.  [Pain management in non-juvenile, aseptic osteonecrosis].

Authors:  M Jäger; A Werner; S Lentrodt; U Mödder; R Krauspe
Journal:  Schmerz       Date:  2004-12       Impact factor: 1.107

10.  Review of the safety and efficacy of imiglucerase treatment of Gaucher disease.

Authors:  Deborah Elstein; Ari Zimran
Journal:  Biologics       Date:  2009-09-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.